83 related articles for article (PubMed ID: 3548432)
1. Asperlicin antagonizes stimulatory effects of cholecystokinin on isolated islets.
Zawalich WS; Diaz VA
Am J Physiol; 1987 Mar; 252(3 Pt 1):E370-4. PubMed ID: 3548432
[TBL] [Abstract][Full Text] [Related]
2. Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718 [corrected].
Zawalich WS; Diaz VA; Zawalich KC
Diabetes; 1988 Oct; 37(10):1432-7. PubMed ID: 3046973
[TBL] [Abstract][Full Text] [Related]
3. Interactions of cholecystokinin and glucose in rat pancreatic islets.
Zawalich W; Takuwa N; Takuwa Y; Diaz VA; Rasmussen H
Diabetes; 1987 Apr; 36(4):426-33. PubMed ID: 3028890
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin-induced alterations in beta-cell sensitivity. Duration, specificity, and involvement of phosphoinositide metabolism.
Zawalich WS; Diaz VA; Zawalich KC
Diabetes; 1987 Dec; 36(12):1420-4. PubMed ID: 2824261
[TBL] [Abstract][Full Text] [Related]
5. Effect of cholecystokinin on the accumulation of inositol phosphates in isolated pancreatic islets.
Florholmen J; Malm D; Vonen B; Burhol PG
Am J Physiol; 1989 Dec; 257(6 Pt 1):G865-70. PubMed ID: 2692460
[TBL] [Abstract][Full Text] [Related]
6. The conditions under which rat islets are labelled with [3H]inositol alter the subsequent responses of these islets to a high glucose concentration.
Zawalich WS; Zawalich KC; Rasmussen H
Biochem J; 1989 May; 259(3):743-9. PubMed ID: 2658979
[TBL] [Abstract][Full Text] [Related]
7. Influence of cAMP and calcium on [3H]inositol efflux, inositol phosphate accumulation, and insulin release from isolated rat islets.
Zawalich WS; Diaz VA; Zawalich KC
Diabetes; 1988 Nov; 37(11):1478-83. PubMed ID: 2846390
[TBL] [Abstract][Full Text] [Related]
8. CCKA receptor antagonism inhibits mechanisms underlying CCK-8-stimulated insulin release in isolated rat islets.
Karlsson S; Ahrén B
Eur J Pharmacol; 1991 Sep; 202(2):253-7. PubMed ID: 1666367
[TBL] [Abstract][Full Text] [Related]
9. Synergistic impact of cholecystokinin and gastric inhibitory polypeptide on the regulation of insulin secretion.
Zawalich WS
Metabolism; 1988 Aug; 37(8):778-81. PubMed ID: 2841557
[TBL] [Abstract][Full Text] [Related]
10. Forskolin-induced desensitization of pancreatic beta-cell insulin secretory responsiveness: possible involvement of impaired information flow in the inositol-lipid cycle.
Zawalich WS; Zawalich KC
Endocrinology; 1990 May; 126(5):2307-12. PubMed ID: 1691696
[TBL] [Abstract][Full Text] [Related]
11. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
[TBL] [Abstract][Full Text] [Related]
12. Biochemical mechanisms involved in monomethyl succinate-induced insulin secretion.
Zawalich WS; Zawalich KC
Endocrinology; 1992 Aug; 131(2):649-54. PubMed ID: 1322278
[TBL] [Abstract][Full Text] [Related]
13. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.
Chang RS; Lotti VJ; Monaghan RL; Birnbaum J; Stapley EO; Goetz MA; Albers-Schönberg G; Patchett AA; Liesch JM; Hensens OD
Science; 1985 Oct; 230(4722):177-9. PubMed ID: 2994227
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 1 is a potent stimulator of islet insulin secretion and phosphoinositide hydrolysis.
Zawalich WS; Zawalich KC
Am J Physiol; 1989 Jan; 256(1 Pt 1):E19-24. PubMed ID: 2536231
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats.
Gasslander T; Lilja I; Smeds S; Lundquist I; Ihse I
Diabetes Res; 1991 Nov; 18(3):135-42. PubMed ID: 1841824
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 alpha exerts glucose-dependent stimulatory and inhibitory effects on islet cell phosphoinositide hydrolysis and insulin secretion.
Zawalich WS; Zawalich KC; Rasmussen H
Endocrinology; 1989 May; 124(5):2350-7. PubMed ID: 2539976
[TBL] [Abstract][Full Text] [Related]
17. Endogenous opioids modulate the effect of cholecystokinin on insulin release in dogs.
Schusdziarra V; Lenz N; Rewes B; Pfeiffer EF
Neuropeptides; 1984 Nov; 4(6):507-17. PubMed ID: 6096758
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.
Bock MG; DiPardo RM; Rittle KE; Evans BE; Freidinger RM; Veber DF; Chang RS; Chen TB; Keegan ME; Lotti VJ
J Med Chem; 1986 Oct; 29(10):1941-5. PubMed ID: 3761313
[TBL] [Abstract][Full Text] [Related]
19. Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans.
Verspohl EJ; Ammon HP; Williams JA; Goldfine ID
Diabetes; 1986 Jan; 35(1):38-43. PubMed ID: 3000856
[TBL] [Abstract][Full Text] [Related]
20. Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties.
Goetz MA; Lopez M; Monaghan RL; Chang RS; Lotti VJ; Chen TB
J Antibiot (Tokyo); 1985 Dec; 38(12):1633-7. PubMed ID: 3005212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
